Thymol Enhances 5-Fluorouracil Cytotoxicity by Reducing Migration and Increasing Apoptosis and Cell Cycle Arrest in Esophageal Cancer Cells: An In-vitro Study
Indian Journal of Clinical Biochemistry · 2025-07 · 40 (3) · 422-433
DOI: 10.1007/s12291-024-01219-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Clinical Biochemistry, online erschienen am 13.04.2024. Verfasst von Ghazaleh Pouyamanesh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Mashhad University of Medical Sciences.
Abstract (Originalsprache)
Esophageal cancer (EC) is a common cancer globally and has a low survival rate because it is often diagnosed at a late-stage, and is frequently chemotherapy resistant. Thymol is found in the herb thyme and has been reported to have potential anticancer properties. We aimed to explore the effects of thymol on the efficacy of 5-Fluorouracil (5-FU) treatment in an in vitro model of EC. We evaluated the synergistic effects of thymol with 5-FU using cell viability, apoptosis, cell cycle analysis, scratch wound healing assay, gelatin zymography, as well as reactive oxygen species (ROS) generation aproaches. The results indicated that thymol significantly decreased the viability of KYSE-30 cells in a time and dose-dependently. However, thymol had a minimal cytotoxic effect against normal fibroblasts. In addition, thymol significantly increased the chemosensitivity of EC KYSE-30 cells to 5-FU by promoting early and late apoptosis, inducing Sub-G1 and G2/M cell cycle arrest, and increasing ROS generation. Combination therapy of thymol with 5-FU also resulted in an increased expression of p53 and Bax, decreased expression of Bcl2, reduced activity of MMP-2, and reduced cell migration compared to single therapies. These findings suggest that thymol has the potential to promote the anticancer potency of 5-FU chemotherapy and inhibit metastasis. However, further studies using animal models are necessary to validate these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
- Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- School of Health and Social Care, Swansea University, Wales, UK.
- Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Sistan and Baluchestan Province Iran.
- Medical School, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Förderung
- Mashhad University of Medical Sciences
Zitieren
APA
Pouyamanesh, G., Ameli, N., Metanat, Y., Khorrami, A., Abbasinezhad-Moud, F., Qoorchi Moheb Seraj, F., Ferns, G. A., & Bahrami, A. (2025). Thymol Enhances 5-Fluorouracil Cytotoxicity by Reducing Migration and Increasing Apoptosis and Cell Cycle Arrest in Esophageal Cancer Cells: An In-vitro Study. Indian Journal of Clinical Biochemistry, 40(3), 422-433. https://doi.org/10.1007/s12291-024-01219-7
Vancouver
Pouyamanesh G, Ameli N, Metanat Y, Khorrami A, Abbasinezhad-Moud F, Qoorchi Moheb Seraj F, et al. Thymol Enhances 5-Fluorouracil Cytotoxicity by Reducing Migration and Increasing Apoptosis and Cell Cycle Arrest in Esophageal Cancer Cells: An In-vitro Study. Indian Journal of Clinical Biochemistry. 2025;40(3):422-433. doi:10.1007/s12291-024-01219-7
BibTeX
@article{Pouyamanesh2025,
author = {Pouyamanesh, Ghazaleh and Ameli, Nima and Metanat, Yekta and Khorrami, Azar and Abbasinezhad-Moud, Farzaneh and Qoorchi Moheb Seraj, Farid and Ferns, Gordon A and Bahrami, Afsane},
title = {Thymol Enhances 5-Fluorouracil Cytotoxicity by Reducing Migration and Increasing Apoptosis and Cell Cycle Arrest in Esophageal Cancer Cells: An In-vitro Study},
journal = {Indian Journal of Clinical Biochemistry},
year = {2025},
volume = {40},
number = {3},
pages = {422--433},
doi = {10.1007/s12291-024-01219-7}
}
EUVIMED